Available online on 15.08.2024 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access

Review Article

Unraveling the Frontiers of Nanomedicine: Exploring Advancements and Envisioning the Future

Shivam Rongpi[1], Injamul Islam[2], Ananta Choudhury[3], Charlisar Teron[1]*

[1]Scholar, Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India.

[2]Assistant Professor, Department of Pharmaceutics, Rahman Institute of Pharmaceutical Sciences and Research, Tepesia, Kamarkuchi, Kamrup(M), Assam India

[3]Professor, Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India.

ABSTRACT

Nanomedicine is an emerging field at the junction of nanotechnology and medicine that provides high-order therapeutic solutions for different diseases. This review discusses the latest developments and future directions in nanomedicine applications in diverse areas of drug delivery, diagnostics, and tissue regeneration.Nanoparticles are engineered at the nanoscale level and, hence, play a very significant role in targeted drug delivery, improving the efficacy of drugs with reduced side effects. This has resulted in recent developments that include the functionalization of nanoparticles that can attach precisely to specific cells or tissues and stimuli-responsive nanoparticles for the controlled release of drugs depending upon environmental triggers.Nanoparticles also revolutionize medical imaging and diagnostics by acting as contrast reagents and sensitive and accurate imaging methods. In this context, SPIONs enhance magnetic resonance imaging, while gold nanoparticles improve optical imaging modalities due to their unique properties.NPs have been proven to be very useful for therapeutic applications, including cancer therapy, gene therapy, and regenerative medicine. Moreover, liposomes and polymer-based nanoparticles can deliver target drugs, lowering systemic toxicity at the tumor site. MSNPs ferry growth factors for tissue repair or act as scaffolds for cell transplantation.Compared to all of the possible benefits of nanomedicine, ensuring the safety and nontoxicity of nanoparticles overwhelmingly comes first. Researchers are working on analyses of the long-term interactions between nanoparticles and biological systems and developing appropriate regulatory frameworks that will enable the safe and responsible use of these materials.The potential for nanomedicine to create opportunities in personalized medicine, combined therapies, and "smart" treatments is considerable. However, to come up with that kind of future vision, enormous challenges lie in the pathway forward—which especially includes regulatory approval and the creation of scalable pathways for manufacturing.

Keywords: Drug delivery, Nanomedicines, Regulatory, Nanoparticles

ARTICLE INFO: Received 14 March 2024; Review Complete 17 June 2024; Accepted 7 August 2024. ; Available online 15 August 2024

Cite this article as:
Rongpi S, Islam I, Choudhury A, Teron C, Unraveling the Frontiers of Nanomedicine: Exploring Advancements and Envisioning the Future, Asian Journal of Pharmaceutical Research and Development. 2024; 12(4):126-132,
DOI: http://dx.doi.org/10.22270/ajprd.v12i4.1452

*Address for Correspondence:
Charlisar Teron, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India.

INTRODUCTION

Nanomedicine, a rapidly advancing medical field, harnesses nanotechnology to devise therapeutic approaches for diverse ailments. Nanomedicines engineered to target specific anatomical locales serve as conduits for drug delivery, diagnostics, and tissue rejuvenation. A notable application pertains to the treatment of various cancers, including breast, gynecological, solid tumor, lung, mesenchymal tissue, carcinoma, central nervous system, and Genito-urinary cancers. Facilitating clinical trials, the U.S. Food and Drug Administration (FDA) has sanctioned multiple investigational new drug (IND) applications for nano formulations[1].Nanomedicines exhibit potential for diagnostic applications akin to biosensors detecting body biomarkers [2].

Furthermore, they hold promise for tissue repair, reminiscent of deploying nanomaterials to transport stem cells to injury sites. The journey of nanomedicine development remains dynamic, embracing a spectrum of methodologies.Liposomes, microemulsions, nanosuspensions, solid dispersions, particle arrangements, co-dissolvability, lipophilic assemblies, and salt formulations constitute several explored approaches[3].



Figure 1: Types of nanoparticles and their different shapes

Foreseeing the future of heightened effectiveness and efficiency, ongoing research endeavors are striving to enhance drug delivery, pharmacokinetics, and tissue engineering [4]. As the evolution of nanomedicine has progressed, its pivotal role in combating disease has increased, underscoring its promise as an indispensable therapeutic paradigm.

BACKGROUND:

The inception of nanomedicine traces back to 1959, marked by physicist Richard Feynman's seminal lecture titled "There is Plenty of Room at the Bottom"[5]. In this discourse, Feynman postulated the feasibility of manipulating individual atoms and molecules, thereby catalyzing the generation of novel materials and devices endowed with enigmatic attributes. The integration of nanotechnology with pharmaceuticals took root during the 1990s with the advent of nanoscale drug delivery systems. An exemplar of this evolution materialized in 1995 with the introduction of Doxil, the inaugural FDA-approved nanomedicine designed for combatting ovarian cancer[6]. Founded upon liposomal encapsulation, Doxil orchestrated targeted drug conveyance, ushering doxorubicin toward cancerous cells while attenuating the adverse effects associated with conventional chemotherapy.

The trajectory of nanomedicine has subsequently undergone numerous strides, epitomized by the diversification of nanoparticle species to cater to drug delivery, imaging, and sensing imperatives. In 2006, a milestone ensued in the form of the inaugural human trial of a nanoparticle-based oncological remedy, showing promising outcomes in the treatment of solid tumors [7]. The contemporary landscape has sparked burgeoning enthusiasm for the interface of nanotechnology with regenerative medicine. Here, nanoparticles orchestrate the conveyance of growth factors and stem cells, fostering tissue rejuvenation—a testament underscored by sanguine outcomes in mitigating spinal cord injuries, heart ailments, and diabetes [8].

Notwithstanding the strides achieved, the realm of nanomedicine grapples with a nascent status, wherein formidable hurdles, notably the biocompatibility and toxicity of nanoparticles, necessitate resolution. Nonetheless, the panorama teems with boundless prospects, as the confluence of nanotechnology with pharmaceutical sciences portends a promising odyssey, engendering fervent anticipation for the prospects heralded by this burgeoning discipline.

CURRENT ADVANCES IN NANOMEDICINES:

Targeted Drug Delivery through Nanoparticles: Enhancing Efficacy and MinimizingSide Effects:

Nano-facilitated targeted drug delivery presents a paradigm shift from conventional techniques, exhibiting significant potential in directing medications to specific cells or tissues. This precision-oriented approach leads to heightened effectiveness and reduced side effects in comparison to traditional methods. Recent advancements in this field encompass functionalized nanoparticles, improved nanocarriers, and stimuli-responsive nanoparticles, such as liposomes, dendrimers, and polymeric nanoparticles, along with pH- or temperature-responsive variants, ushering in a new era of precise drug delivery [9].



Figure 2: Nanoparticles attached to targeting molecules to achieve targeted drug delivery

Key developments:

a. Functionalized Nanoparticles: Incorporating ligands or antibodies onto nanoparticle surfaces enables specific binding and entry into predetermined cells or tissues.

b. Stimuli-Responsive Nanoparticles: Nanoparticles engineered to release drugs in response to triggers such as changes in pH or temperature offer controlled release mechanisms.

Promise and Patient Benefits:

Current research and development efforts in this realm area hold immense potential for refining medication delivery systems. The amalgamation of functionalized nanoparticles and stimuli-responsive variants promises to revolutionize patient outcomes and quality of life [10].

Clinical Example: Abraxane® - Precision in Nanomedicine:

Abraxane® exemplifies the success of targeted medication delivery via nanomedicine. This clinical application employs nab-paclitaxel, a nanoparticle-based formulation of the chemotherapeutic agent paclitaxel. Abraxane® is designed to treat various cancers, including breast cancer, non-small cell lung cancer, and pancreatic cancer, and it employs human serum albumin nanoparticles, which are stable and prolong circulation in the bloodstream [11].

Nanoparticle-Specific Targeting: The albumin nanoparticles in Abraxane® can bind to SPARC, a protein often overexpressed in certain cancer cells, facilitating the selective targeting of these cells [12].

Enhanced efficacy and reduced toxicity: Compared with traditional paclitaxel formulations, Abraxane® showcases improved effectiveness and reduced toxicity. The targeted delivery of medicine through nanoparticles results in a greater impact at the intended site, underpinning its wide clinical usage and regulatory approvals across multiple nations [13].

In conclusion, the synergy between targeted drug delivery and nanoparticle technology is reshaping medical approaches. The incorporation of functionalized nanoparticles and stimuli-responsive systems signals a transformative trajectory in enhancing patient experiences and outcomes, as demonstrated by clinical examples such as Abraxane®. This evolving landscape holds promise for the advancement of precision and effective medication delivery.

Nanoparticles for Imaging and Diagnostics:

Medical imaging is crucial for disease diagnosis and treatment and can reveal disease characteristics, including location, size, and progression. Recent advancements have highlighted the use of nanoparticles as promising contrast agents, increasing the sensitivity and precision of imaging. This evolution holds the potential for hastened and more accurate diagnosis and treatment interventions.

NPs have emerged as a suitable choice for medical imaging contrast agents because of their unique attributes. Their diminutive dimensions facilitate cellular entry and tissue penetration, while surface chemistry modifications empower cell or tissue targeting. Furthermore, nanoparticles stand out in imaging methods such as optical imaging due to their capacity to emit or scatter light [14].



Figure 3: Radiolabeled nanoparticles used for different imaging techniques

Examples of Nanoparticle Contrast Agents:

a. Superparamagnetic Iron Oxide Nanoparticles (SPIONs): SPIONs, employed as contrast agents in magnetic resonance imaging (MRI), exemplify nanoparticle-based solutions. Their substantial signal variations in MR images, coupled with a robust magnetic moment, render SPIONs optimal for imaging tissues such as the liver and lymph nodes. Enhanced MRI specificity and sensitivity are achieved through targeted SPION localization [15].

b. Gold nanoparticles: Because of their distinct optical properties, gold nanoparticles constitute another class of nanoparticle-based imaging agents. Particularly suited for techniques such as optical coherence tomography (OCT) and photoacoustic imaging (PAI), these nanoparticles enable precise imaging. Gold nanoparticles functionalized with targeting ligands and antibodies enable targeted imaging of specific tissues [16].

Conclusion Insights:

The integration of nanoparticles as contrast agents represents a transformative advancement in medical imaging. Their capacity to enhance imaging precision, coupled with targeted localization capabilities, augments diagnostics and therapeutic interventions. From superparamagnetic iron oxide nanoparticles to gold nanoparticles, these nanoscale entities redefine the scope of medical imaging, providing promising refined disease insights and better patient outcomes.

Nanoparticles for therapeutic applications

By harnessing their distinct physicochemical attributes and surface functionalization potential, nanoparticles have emerged as pivotal tools in therapeutics. Conventional therapeutic drugs have drawbacks, including inadequate biodistribution, unfavorable side effects, minimal efficacy, and non-selectivity [17]. There have been remarkable advancements in nanoparticle-based therapeutic strategies, particularly in cancer treatment, gene therapy, and regenerative medicine [18].

Nanoparticles in Cancer Treatment:

NPs have emerged as revolutionary carriers in cancer therapy, aiming to enhance treatment efficacy while minimizing the systemic toxicity associated with traditional chemotherapy. Among the various nanoparticle platforms, liposomes and polymer-based nanoparticles have gained significant attention. These nanoparticles encapsulate chemotherapeutic agents, shielding them from premature degradation and allowing for targeted drug delivery directly to tumor sites [19].

Liposomes, which are composed of phospholipids, mimic the structure of cell membranes and can effectively encapsulate both hydrophilic and hydrophobic drugs. Their inherent biocompatibility and ability to evade immune detection make them ideal candidates for drug delivery. Polymer-based nanoparticles, on the other hand, offer greater stability and versatility. They can be engineered from various synthetic or natural polymers, allowing for precise control over their size, shape, and surface properties [20].

Incorporating targeting moieties, such as antibodies or peptides, further enhances the specificity of nanoparticles for cancer cells [21]. These targeting moieties bind to specific receptors overexpressed on cancer cells, facilitating the selective accumulation of nanoparticles at the tumor site. This targeted drug delivery approach minimizes the exposure of healthy tissues to chemotherapeutic agents, reducing the risk of side effects and improving therapeutic outcomes.

The use of nanoparticles in cancer therapy holds tremendous promise for revolutionizing treatment paradigms. By combining the unique properties of nanoparticles with advancements in targeted drug delivery and controlled release, researchers aim to improve the therapeutic index of chemotherapeutic agents and ultimately enhance patient outcomes.



Figure 4: Mechanism of nanoparticles in cancer cells

Nanoparticles in Regenerative Medicine: Accelerating Tissue Repair

In regenerative medicine, nanoparticles serve as versatile tools for facilitating tissue repair and regeneration. One notable type of nanoparticle is mesoporous silica nanoparticles (MSNPs), which have a porous structure that allows for the encapsulation and delivery of various therapeutic agents. MSNPs can be engineered to carry growth factors and signaling molecules to injured tissue sites, where they stimulate the regrowth of damaged tissue. The unique properties of MSNPs make them ideal drug delivery platforms because they can protect encapsulated molecules from degradation and release them in a controlled manner over time [22].

In addition to their drug delivery capabilities, nanoparticles offer a promising cell transplantation approach. They can serve as transport media or scaffolds for cells, enabling their efficient delivery to specific tissue sites requiring

regeneration. The porous structure of MSNPs provides a favorable environment for cell attachment, growth, and differentiation. By providing a supportive framework, nanoparticles help protect transplanted cells from the harsh conditions of the transplantation site, increasing their chances of survival and integration into the surrounding tissue [23].

The combination of drug delivery and cell transplantation using nanoparticles offers significant potential for regenerative medicine. By delivering growth factors and signaling molecules to injured tissues while simultaneously providing a supportive environment for transplanted cells, nanoparticles can enhance the healing process and promote tissue regeneration [24]. This approach holds promise for treating a wide range of conditions, from chronic wounds to degenerative diseases, and offers hope for improved patient outcomes.



Figure 5: Nanoparticles as a regenerative medicine for wound healing

THE SAFETY AND TOXICITY OF NANOPARTICLES:

The increasing application of nanoparticles, particularly in the field of medicine, is a matter of concern because of their safe use and possible toxicity. NPs have been very promising for therapy and diagnostics; however, the long-term effects and risks associated with their application remain unclear. Recently, much research has focused on understanding the toxicity and safety profiles of nanoparticles and detecting associated hazards [25].

Challenge of Safety and Toxicity Assessment

Diverse physicochemical properties: Nanoparticles range from their size, shape, and surface charge to their chemical composition. Diversity in these aspects can result in a high impact on biodistribution, cellular uptake, and toxicity, and hence, an accurate assessment of the safety aspects becomes rather challenging. Most of the research has shown that titanium dioxide nanoparticles, which are normally used in sunscreen and cosmetic products, can elicit inflammatory responses and oxidative stress [26].

Complexity in interactions with biological systems: The interactions between nanoparticles and biological systems could be very complex, as they affect different organs and tissues. Many studies have investigated the influence of nanoparticles on the liver, kidneys, lungs, and immune system to determine their negative effects [27]. For instance, some types of nanoparticles are concentrated in the liver in a dose-dependent manner and may further trigger liver damage with long-term exposure [28].

Regulatory Frameworks and Standards

Several regulatory bodies and organizations have established standards and guidelines for nanoparticle applications, especially in medicine. These frameworks aim to ensure the safe and responsible use of nanoparticles by balancing their potential benefits with potential risks. The U.S. Food and Drug Administration (FDA), for example, have issued guidance on the safety assessment of nanomaterials in drug products [29].

Mitigation Strategies

Several strategies have been developed to mitigate the potential toxicity of nanoparticles. These include:

Surface Modifications: Surface engineering of nanoparticles with coating/functional groups alters their interactions with biological systems, which further reduces their toxicity.

Biodegradable Materials: Synthesis of the biodegradable material Torrential reduces nanoparticle accumulation in the body and hence long-term risks [30].

Targeted Delivery: Formulations for targeted drug delivery of nanoparticles, which reduces their exposure to healthy tissues and hence possible side effects [31].

This means that by addressing nanoparticle safety and toxicity issues, the responsible development and application of nanomedicine will be guaranteed for the sake of sustaining human health.

FUTURE SCENARIOS FOR NANOMEDICINE:

Personalized Medicine: Lose the Precision

One of the lines of nanomedicine development that may follow is personalized medicine. NPs, which act as delivery vectors, could usher in an age of massively individualized treatments tailored to the genotype, case history, and lifestyle habits of a given individual. This extremely personalized approach, at the patient level, offers tremendous potential for enhancing treatment outcomes and tailoring medical interventions. [32]

Combination Therapies: Multifaceted Solutions

Combination medicines will be the new frontier in development. NPs, which are adept at carrying multiple drugs, reveal one potential prospective solution for intricate ailments such as cancer. Thus, this approach can revolutionize treatments by administering a cocktail of medications all in one go, probably improving its efficacy while reducing side effects. [33]

"Smart" Treatments: Responsive Interventions

The arena in which this promise of "smart" treatments may lie is the development of strategies aimed at programming/these nanoparticles to release a drug upon specific biological cues. Harnessed effectively, such triggers could contribute to avoiding adverse effects while boosting therapeutic efficacy—the way forward toward high therapeutic precision [34].

Challenges and Expectations: Paving the Way Forward

The first and foremost challenge on the roadmap of nanomedicine is regulatory approval. The safety and efficacy of nanoparticles dictate very stringent standards and guidelines that should be met. Ensuring that this obstacle is overcome would prove a breakthrough at the juncture when nanomedicine reaches mainstream healthcare.

Manufacturing Advancements: Scaling Up for Wider Impact

One such critical bottleneck toward growth in nanomedicine is efficient manufacturing procedures. The present manufacturing processes can be very time-consuming and costly, which limits their wide-scale incorporation. This will facilitate the broader incorporation of nanomedicine technology upon the removal of such limitations.

CONCLUSION:

Nanomedicine, fueled by advancements in nanotechnology, is revolutionizing healthcare by offering innovative solutions for targeted drug delivery, enhanced diagnostics, and regenerative medicine. NPs, with their unique properties and customizable features, have emerged as powerful tools for fighting diseases such as cancer. Although the potential of nanomedicine is immense, addressing safety concerns and establishing robust regulatory frameworks are crucial for its widespread implementation. Continued research and collaboration between scientists, clinicians, and regulatory bodies will pave the way for nanomedicine to transform healthcare and improve patient outcomes.

CONFLICT OF INTEREST:

The author declares that there is no conflict of interest.

REFERENCE:

1. National Cancer Institute. Current Treatments [Internet]. Bethesda: National Cancer Institute; [cited 2024 Jul 10]. Available from: https://www.cancer.gov/nano/cancer-nanotechnology/current-treatments
2. European Technology Platform on Nanomedicine. What Is Nanomedicine? [Internet]. European Technology Platform on Nanomedicine; [cited 2024 Jul 10]. Available from: https://etp-nanomedicine.eu/about-nanomedicine/what-is-nanomedicine/
3. Pilli GD, Elumalai K, Muthukumar VA, Sundaram PS. A revised analysis of current and emerging Nano suspension technological approaches for cardiovascular medicine. Beni-Suef University Journal of Basic and Applied Sciences. 2022 Jan 15;11(1):10.
4. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 1;9(6).
5. Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of pharmaceutical investigation. 2018 Jan;48(1):43-60.
6. Feynman R. There's plenty of room at the bottom. Eng Sci. 1960;23:22-36.
7. Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.
8. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences. 2020 Aug 20;7:193.
9. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Advanced drug delivery reviews. 2006 Dec 1;58(14):1456-9.
10. Jain KK. Advances in the field of nanomedicine. Drug Discov Today. 2015;20(2):145-52.
11. D'Costa G, Pisal DS, Rane AV. Report on Synthesis of nanoparticles and functionalization: Co precipitation method.
12. Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Frontiers in bioengineering and biotechnology. 2023 Apr 13;11:1177151.
13. Pantidos N, Horsfall LE. Biological synthesis of metallic nanoparticles by bacteria, fungi and plants. Journal of Nanomedicine & Nanotechnology. 2014 Sep 1;5(5):1.
14. Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology. 2009 Jun 1;86(3):215-23.
15. Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F. Nanoparticles and targeted drug delivery in cancer therapy. Immunology letters. 2017 Oct 1;190:64-83.
16. Desai N. Nab-paclitaxel formulation: Abraxane®. The Oncologist. 2006;12(7):902-12.
17. Zhao M, Lei C, Yang Y, Bu X, Ma H, Gong H, Liu J, Fang X, Hu Z, Fang Q. Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp. PloS one. 2015 Jul 16;10(7):e0131429.
18. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990 May;175(2):494-8.
19. Chen Y, Yang J, Fu S, Wu J. Gold nanoparticles as radiosensitizers in cancer radiotherapy. International Journal of nanomedicine. 2020 Nov 24:9407-30.
20. Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. Journal of nuclear medicine. 2014 Dec 1;55(12):1919-22.
21. Chaudhury K, Kumar V, Kandasamy J, RoyChoudhury S. Regenerative nanomedicine: current perspectives and future directions. International journal of nanomedicine. 2014 Sep 1:4153-67.

22. Patel P, Shah J. Safety and toxicological considerations of nanomedicines: the future directions. Current Clinical Pharmacology. 2017 May 1;12(2):73-82.

23. Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M. Safety of nanoparticles in medicine. Current drug targets. 2015 Dec 1;16(14):1671-81.

24. Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. Journal of nanomaterials. 2019;2019(1):3702518.

25. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy–Strategies and perspectives. Journal of Controlled Release. 2016 Oct 28;240:489-503.

26. Nune SK, Gunda P, Thallapally PK, Lin YY, Laird Forrest M, Berkland CJ. Nanoparticles for biomedical imaging. Expert opinion on drug delivery. 2009 Nov 1;6(11):1175-94.

27. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon. 2022 May 1;8(5).

28. 28.Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences. 2020 Aug 20;7:193.

29. U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Safety of Nanomaterials in Cosmetic Products. Retrieved from

30. Hasan A, Morshed M, Memic A, Hassan S, Webster TJ, Marei HE. Nanoparticles in tissue engineering: applications, challenges and prospects. International journal of nanomedicine. 2018 Sep 24:5637-55.

31. Hong IS. Enhancing stem cell-based therapeutic potential by combining various bioengineering technologies. Frontiers in Cell and Developmental Biology. 2022 Jul 5;10:901661.

32. Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M. Safety of nanoparticles in medicine. Current drug targets. 2015 Dec 1;16(14):1671-81.

33. Rashid MM, Forte Tavčer P, Tomšič B. Influence of titanium dioxide nanoparticles on human health and the environment. Nanomaterials. 2021 Sep 10;11(9):2354.

34. Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm. 2023 Aug;4(4):e327.